Arcus Biosciences Q4 Earnings Call Highlights

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• HIF-2α inhibition is 'the only new class' on the horizon and the field is a '2-horse race' between belzutifan and casdatifan

  80% confidence

• No additional immune-related adverse events had been seen since the volrustomig dose reduction in AstraZeneca collaboration, and no primary progression was observed in the small dataset

  80% confidence

• TNF program is aiming for a selective TNF receptor 1 approach and expects to enter the clinic in late 2026 or early 2027

  80% confidence

• RCC drug sales in select major markets exceed $10 billion annually and are anticipated to grow to $13 billion by 2030

  80% confidence

• Internal peak sales estimates for casdatifan include $2.5 billion in the IO-experienced setting targeted by PEAK-1 and $3 billion or more in first line; these represent revenue opportunity to Arcus rather than total addressable market

  80% confidence

• A key differentiator for casdatifan is a consistently low 'primary progression' rate (progression at or before first scan), which is especially important early in therapy

  80% confidence

• Arcus expects operating expenses to decrease meaningfully versus 2025; magnitude of decrease could depend on results of forthcoming STAR-121 futility analysis expected in the 'next couple of months', with more detailed R&D guidance to come on the Q1 call

  80% confidence

• The company's goal is to complete PEAK-1 enrollment by year-end

  80% confidence

• Casdatifan data compares favorably to belzutifan in late-line ccRCC, citing belzutifan's 5.6-month PFS versus casdatifan's longer progression-free survival and higher response rates

  80% confidence

• Arcus expects its cash and investments to fund operations until at least the second half of 2028

  80% confidence

• Detailed results from Merck's Phase III LITESPARK-011 (belzutifan plus lenvatinib versus cabozantinib) expected at ASCO GU could be 'validating' and supportive of enrollment momentum for PEAK-1

  80% confidence

• 100 mg once daily has been selected as the 'optimal go-forward dose' for casdatifan

  80% confidence

• Arcus expects 'at least two' additional casdatifan data presentations later in 2026, including updated results from casdatifan plus cabozantinib cohort with minimum 12 months follow-up and new data from ARC-20 casdatifan plus Zim cohort

  80% confidence

• Even if all censored patients progressed at the next scan, median PFS would still be 14.4 months

  80% confidence

• MRGPRX2 program is expected to enter the clinic later this year, beginning with a healthy volunteer Phase I study and then a proof-of-concept study in chronic inducible urticaria, with potential proof-of-concept data within nine to 12 months after clinical entry

  80% confidence

• Belzutifan's reported primary progression rate is 35% as monotherapy in its Phase III trial, and belzutifan will likely require combination with a TKI in frontline disease to keep early progression low

  80% confidence

• Arcus's I&I portfolio comprises five programs, with focus on validated targets where small molecules have historically been difficult to develop

  80% confidence

• Arcus plans to share data from the 'CAS plus Zim' cohort in the second half of the year

  80% confidence

• Arcus retains rights to casdatifan economics except in Japan and certain Southeast Asian countries

  80% confidence

• Ipilimumab/nivolumab shows primary progression of about 20-25% and PFS of roughly 12 months, with outcomes from CheckMate 214 and COSMIC-313 being 'very, very similar'

  80% confidence

• PEAK-1 is actively enrolling and described as a 'fast-to-market strategy' with a sole primary endpoint of PFS that could enable a relatively quick readout

  80% confidence

• Arcus wants to demonstrate 'meaningful improvement' over ipilimumab/nivolumab, with particular emphasis on reducing the primary progression rate

  80% confidence

• Merck's KEYMAKER-U02A presence at ASCO GU is a 'trial in progress' poster without belzutifan data

  80% confidence

• Belzutifan is already generating an annual run rate of 'nearly $1 billion'

  80% confidence

• Updated ARC-20 analysis reflects January 30 data cutoff from four late-line monotherapy cohorts; this is the fourth time Arcus has presented single-agent casdatifan data in that setting and efficacy has continued to improve with longer follow-up

  80% confidence

• Arcus's goal is to establish casdatifan as a 'best-in-class' HIF-2α inhibitor for ccRCC

  80% confidence